Folgen

  • Fixing the Body's Shield: A New Way to Fight Neurodegenerative Diseases

    Fixing the Body's Shield: A New Way to Fight Neurodegenerative Diseases
    Feb 11 2026
    What if helping the immune system find balance could meaningfully slow disease progression for diseases like ALS or Alzheimer’s? In this episode of Rx for Biotech, host Chris Leidli sits down with Arun Swaminathan, CEO of Coya Therapeutics, to talk about a new and hopeful approach to treating neurodegenerative diseases by calming harmful inflammation in the body. This conversation offers a hopeful look at how science is working to improve quality of life for patients and families facing neurodegenerative disease. Arun also shares insights from his 20+ years in biotech leadership, including what it takes to advance novel immunology science in high-unmet-need indications and build a product pipeline across neurodegenerative, autoimmune, and inflammatory diseases.
    Mehr anzeigen Weniger anzeigen
    33 Min.
  • How to Advocate for Yourself in Cancer Care: Insights from a Top Oncologist

    How to Advocate for Yourself in Cancer Care: Insights from a Top Oncologist
    Jan 27 2026
    A cancer diagnosis can feel overwhelming - but patients are not powerless. In this episode, Dr. Nainesh Parikh of Moffitt Cancer Center explains how patients and families can better advocate for themselves, navigate complex healthcare systems, and get connected to the right care at the right time.
    Mehr anzeigen Weniger anzeigen
    40 Min.
  • A New Hope for Skin Cancer: The Story Behind a Promising Immunotherapy

    A New Hope for Skin Cancer: The Story Behind a Promising Immunotherapy
    Jan 15 2026
    This episode is about hope, and about a different way of thinking about cancer treatment. My guest is Dr. Øystein Rekdal, CEO and co-founder of Lytix Biopharma. Øystein is a scientist and leader who has spent decades studying how the immune system works - and how it can be helped to recognize and fight cancer more effectively. Rather than focusing only on destroying tumors, Lytix is working on therapies designed to wake up the immune system and help it remember cancer as a threat. It’s an approach that aims not just to treat disease, but to support the body’s own ability to respond. This is a conversation for anyone who wants to better understand where cancer care is headed, and why there’s real reason for optimism.
    Mehr anzeigen Weniger anzeigen
    34 Min.
  • Targeting the Fire Within: How InflaRx Is Redefining Inflammation Control

    Targeting the Fire Within: How InflaRx Is Redefining Inflammation Control
    Nov 20 2025
    InflaRx CEO Dr. Niels Riedmann joins Rx for Biotech to discuss how the company is pioneering complement-directed therapies to control severe inflammation and autoimmune disease. We break down the science behind INF904, and why C5a is such a powerful immune driver, and how precision immunology is shaping the next wave of treatment innovation.
    Mehr anzeigen Weniger anzeigen
    35 Min.
  • How Novel Genetic Medicines may improve treatment of chronic Neurological Diseases

    How Novel Genetic Medicines may improve treatment of chronic Neurological Diseases
    Nov 11 2025
    In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery. EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.
    Mehr anzeigen Weniger anzeigen
    29 Min.
  • Restoring Breath: Biologic Innovation for the Most Vulenerable Patients

    Restoring Breath: Biologic Innovation for the Most Vulenerable Patients
    Oct 28 2025
    Airway Therapeutics is taking on one of the toughest challenges in medicine - helping premature infants breathe on their own. In this episode of Rx for Biotech, CEO Marc Salzberg shares how zelpultide alfa, an investigational, first-in-class biologic, could transform care for newborns with bronchopulmonary dysplasia (BPD) and unlock a new future for respiratory medicine.
    Mehr anzeigen Weniger anzeigen
    21 Min.
  • Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy

    Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy
    Oct 14 2025
    In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.
    Mehr anzeigen Weniger anzeigen
    29 Min.
  • The Alpha Edge: Perspective Therapeutics on the Future of Theranostics and Radiopharmaceutical Therapies

    The Alpha Edge: Perspective Therapeutics on the Future of Theranostics and Radiopharmaceutical Therapies
    Sep 9 2025
    In this episode of Tc for Biotech, host Chris Leidli sits down with Thijs Spoor, CEO of Perspective Therapeutics, to unpack the future of radiopharmaceuticals for the treatment of cancer. This conversation goes beyond the science to explore the infrastructure and strategy that determines success in bringing target cancer therapies to patients.
    Mehr anzeigen Weniger anzeigen
    37 Min.